JW Pharmaceutical Launches "Rivarohigh Jung," a Triple Combination Therapy for Dyslipidemia and Hypertension

Providing an Integrated Treatment Option with Consideration for New-Onset Diabetes Safety

JW Pharmaceutical announced on December 2 that it has launched "Rivarohigh Jung" (active ingredients: pitavastatin, amlodipine, valsartan), a triple combination therapy designed to simultaneously manage dyslipidemia and hypertension.

Libaro High. JW Pharmaceutical

Rivarohigh Jung is a product that combines pitavastatin, a treatment for dyslipidemia, with amlodipine and valsartan, both antihypertensive agents, into a single formulation. It is designed to help patients with both hypertension and dyslipidemia control their blood pressure and low-density lipoprotein cholesterol (LDL-C) at the same time.

As the first triple combination therapy containing pitavastatin to be introduced in Korea, Rivarohigh Jung is available in a total of six dosage strengths, enabling tailored treatment based on the patient’s blood pressure, lipid profile, and comorbidities.

Pitavastatin, the key ingredient in Rivarohigh Jung, has been shown in numerous domestic and international studies to have a lower risk of new-onset diabetes mellitus (NODM) compared to other statins, and is recognized for its glycemic safety. Some studies have also confirmed a significant reduction in the risk of developing diabetes in the pitavastatin group compared to the control group.

To commemorate the launch of Rivarohigh Jung, JW Pharmaceutical held a symposium at the Wyndham Grand Busan Hotel in Busan for two days starting November 29. The symposium was attended by medical professionals, including specialists in cardiology and endocrinology, and clinical usefulness regarding the efficacy and safety of Rivarohigh Jung was shared.

At the symposium, Professor Na Jin-oh of the Cardiovascular Center at Korea University Guro Hospital stated, "The clinical results of Rivarohigh demonstrate improved outcomes for a wide range of patient groups, including those with heart failure and myocardial infarction, indicating broad therapeutic applicability. Accordingly, Rivarohigh Jung is expected to expand the range of treatment options for patients with both hypertension and dyslipidemia."

JW Pharmaceutical plans to implement differentiated marketing strategies targeting patients with hypertension and dyslipidemia accompanied by abnormal blood glucose, such as those with diabetes or metabolic syndrome, leveraging the unique advantages of pitavastatin.

A representative from JW Pharmaceutical said, "With the launch of Rivarohigh Jung, the first pitavastatin-based triple combination therapy in Korea, we are now able to offer a new treatment option for patients with both hypertension and dyslipidemia. In particular, we will provide differentiated treatment options in the cardiovascular and metabolic disease fields through the Rivarohigh family, aiming to effectively reduce cardiovascular risk in patients with diabetes and prediabetes."

This content was produced with the assistance of AI translation services.